Literature DB >> 12423393

Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland.

James P Stables1, Edward H Bertram, H Steve White, Douglas A Coulter, Marc A Dichter, Margaret P Jacobs, Wolfgang Loscher, Daniel H Lowenstein, Solomon L Moshe, Jeffrey L Noebels, Mirian Davis.   

Abstract

PURPOSE: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed.
METHODS: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies.
RESULTS: At the end of the 2-day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure.
CONCLUSIONS: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423393     DOI: 10.1046/j.1528-1157.2002.06702.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  31 in total

Review 1.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

3.  The best model for a cat is the same cat...or is it?

Authors:  Andrey Mazarati
Journal:  Epilepsy Curr       Date:  2007 Jul-Aug       Impact factor: 7.500

4.  Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models.

Authors:  Carl E Stafstrom; Jeffrey C Ockuly; Lauren Murphree; Matthew T Valley; Avtar Roopra; Thomas P Sutula
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 5.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

6.  Genetic backgrounds have unique seizure response profiles and behavioral outcomes following convulsant administration.

Authors:  Nycole Ashley Copping; Anna Adhikari; Stela Pavlova Petkova; Jill Lynn Silverman
Journal:  Epilepsy Behav       Date:  2019-11-04       Impact factor: 2.937

Review 7.  The role of interleukin-1beta in febrile seizures.

Authors:  James G Heida; Solomon L Moshé; Quentin J Pittman
Journal:  Brain Dev       Date:  2009-02-13       Impact factor: 1.961

8.  Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats.

Authors:  Theresa A Lusardi; Kiran K Akula; Shayla Q Coffman; David N Ruskin; Susan A Masino; Detlev Boison
Journal:  Neuropharmacology       Date:  2015-08-06       Impact factor: 5.250

9.  The antiepileptic effect of the glycolytic inhibitor 2-deoxy-D-glucose is mediated by upregulation of K(ATP) channel subunits Kir6.1 and Kir6.2.

Authors:  Heng Yang; Ren Guo; Jiongxing Wu; Yufeng Peng; Dujie Xie; Wen Zheng; Xian Huang; Ding Liu; Wei Liu; Lihua Huang; Zhi Song
Journal:  Neurochem Res       Date:  2013-03-09       Impact factor: 3.996

10.  Calcium channel dysfunction in inferior colliculus neurons of the genetically epilepsy-prone rat.

Authors:  Prosper N'gouemo; Carl L Faingold; Martin Morad
Journal:  Neuropharmacology       Date:  2008-12-06       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.